Autoimmune disease treatment breakthroughs: atacicept, enpatoran, CAR-T expansion, and novel CCL24 antibody
Key Questions
What recent FDA approvals target autoimmune kidney and lupus conditions?
FDA approved atacicept, a dual BAFF/APRIL inhibitor, for IgA nephropathy; enpatoran received breakthrough designation as a TLR7/8 inhibitor for cutaneous lupus.
How is CAR-T expanding into autoimmune diseases?
CD19 CAR-T reaches synovium in RA with sustained autoantibody reduction; therapies are advancing into RA, SSc, and myositis with durability data, plus immune dimming strategies like blinatumomab.
What new dual-CAR therapy received FDA clearance?
Fate Therapeutics won FDA IND clearance for FT839, an off-the-shelf iPSC-derived dual-CAR (CD19/CD38) therapy for autoimmune disease that eliminates conditioning chemotherapy.
FDA approved atacicept (dual BAFF/APRIL inhibitor) for IgA nephropathy; enpatoran (TLR7/8 inhibitor) breakthrough for cutaneous lupus. CAR-T therapy expanding into autoimmune diseases—EULAR 2026 recap shows CD19 CAR-T reaches synovium in RA with sustained autoantibody reduction; relapse biology and BCMA rescue strategies; immune dimming with blinatumomab. CAR-T moving beyond lupus into RA, SSc, myositis with real durability data. New: Fate Therapeutics wins FDA IND clearance for FT839, a dual-CAR (CD19/CD38) iPSC-derived therapy for autoimmune disease, eliminating conditioning chemotherapy. New: Chemomab-Scipher merger advances first-in-class CCL24 antibody nebokitug into AI-guided Phase 2 RA trial, with dual anti-inflammatory/anti-fibrotic mechanism.